AI-generated summary
The authors report a 6-year follow-up of a randomized trial comparing low-level laser therapy with placebo in 43 people with hypothyroidism from chronic autoimmune thyroiditis. They found thyroid nodule frequency was similar between groups, and the laser group needed a lower levothyroxine dose, with antibody levels not differing. The authors conclude the treatment was safe for this use.
- Participants
- 43
- Who or what was studied
- Adults with hypothyroidism induced by chronic autoimmune thyroiditis who had previously taken part in a randomized clinical trial
- Limits stated in the abstract
- The abstract does not report the laser wavelength or dosing, and the small group sizes (25 and 18) limit the strength of the conclusions.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Introduction
A randomized clinical trial (RCT) was performed to evaluate the efficacy of low-level laser therapy (LLLT) for hypothyroidism induced by chronic autoimmune thyroiditis (CAT).
Objective
The objective was to assess the safety and actions of LLLT 6 years after completion of the RCT.
Materials And Methods
Forty-three participants were invited to participate in this study 6 years after completion of the RCT. Twenty-five were subjected to LLLT (group L), and 18 were subjected to placebo (group P). Primary
Outcome Measure
frequency of thyroid nodules, which were subjected to fine-needle aspiration biopsy. Secondary
Outcome Measures
dose of levothyroxine required to treat hypothyroidism, thyroid peroxidase antibodies (anti-TPO), and anti-thyroglobulin antibodies (anti-Tg).
Results
In group L, a nodule was observed in three patients, who all had a Bethesda II classification. In group P, a nodule was also observed in three patients, with two classified as Bethesda II and one as Bethesda III. The levothyroxine dose required by group L was significantly lower than that required by group P (P = 0.002). The anti-TPO and anti-Tg levels did not differ between the groups.
Conclusion
LLLT, by the methods described, has been shown to be safe for the treatment of hypothyroidism resulting from CAT. This trial is registered with ClinicalTrials.gov Identifier: NCT02240563.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Randomized controlled trial, Dose, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.